… transformative RNA therapies based on its proprietary Axiomer® RNA editing technology platform, today announced the … has served on ProQR’s Supervisory Board since 2014. About Axiomer ® ProQR is pioneering a next-generation RNA base …
… ophthalmic programs supports ProQR’s strategic focus on Axiomer® RNA editing platform technology and continued … transformative RNA therapies based on its proprietary Axiomer ® RNA editing technology platform, today reported its …
… trial in 2022. RNA base-editing platform technologies – Axiomer ® and Trident ® ProQR has been further optimizing the Axiomer ® Editing Oligonucleotide (EON) designs and shown … will develop selected genetic eye disease targets with Axiomer ® , and will provide further guidance on this in H2 …
… with Lilly highlights significant potential of ProQR’s Axiomer ® RNA base-editing platform and strengthens financial … 18, 2021 to highlight clinical stage pipeline programs and Axiomer ® RNA editing platform LEIDEN, Netherlands & … the partnership we entered into with Lilly around our Axiomer RNA base-editing platform and the appointment of …
… we are excited by the potential of our next-generation Axiomer RNA editing technology. In addition to using this … this trial in 2022. ProQR has been further optimizing the Axiomer ® Editing Oligonucleotide (EON) designs and will develop selected genetic eye disease targets with Axiomer ® . The Company anticipates providing further …
… in the lives of the communities we serve. Our proprietary Axiomer® RNA editing technology platform enables the editing … nucleotides in RNA using the cells own editing machinery. Axiomer® RNA editing technology harnesses ADAR (Adenosine …
… in the lives of the communities we serve. Our proprietary Axiomer® RNA editing technology platform enables the editing … nucleotides in RNA using the cells own editing machinery. Axiomer® RNA editing technology harnesses ADAR (Adenosine …